Transcript Vaccines

Laboratory Diagnosis
1
Category of Sample
• Blood, Urine, Stool, nasal washing, nasal
swab , throat swab, saliva , sputum, rectal
swab, vesicle fluid( scraping or swab), tissue
,brain biopsy, cerebrospinal fluid, et al.
2
Laboratory Diagnosis
•
•
•
•
•
Microscopy Identification
Virus isolation and identification
Detection of viral proteins( antigens and enzymes)]
Detection of viral genetic material
Serologic procedures
3
Microscopy Identification
• Light microscopy
• Fluorescent microscopy
• Electron microscopy
4
Light microscopy
• Characteristic CPE
• Inclusion Bodies
5
• Cell death
Cell rounding
Degeneration
Aggregation
Loss of attachments to substrate
• Characteristic histological changes:inclusion bodies
in the nucleus or cytoplasm, margination of chromatin
• Syncytia: multinucleated giant cells caused by virusinduced cell-cell fusion
6
Fluorescent microscopy
• Fluorescent-antibody staining
7
Electron microscopy
• Direct detection : Human rotavirus; HAV;
HBV; Smallpox virus; Herpes virus.
• Immune Electron microscopy: Human
rotavirus; HAV;
8
Laboratory Diagnosis
•
•
•
•
•
Microscopy Identification
Virus isolation and identification
Detection of viral proteins( antigens and enzymes)]
Detection of viral genetic material
Serologic procedures
9
Viral isolation and Identification
•
•
•
•
Viral Growth and Cell culture
Viral Detection
Viral Identification
Interpretation of culture results
10
Systems for the Propagation of
Viruses
•
•
•
•
People
Animals: cows, chickens, mice,rats, suckling mice
Embryonated eggs
Organ and tissue culture
Organ culture
Primary tissue culture
Cell lines: diploid
Tumor or （immortalized ）cell line
11
Viral detection
•
•
•
•
CPE
Hemadsorption
Interfere
Metabolize of cell
12
TCID50
(Tissue culture infective dose)
• TCID50 is defined as that dilution of virus
which will cause CPE in 50% of a given batch
of cell culture
• TCID50= log10 of highest dilution giving 100%CPE +1/2 –
(total number of test units showing CPE)/
(number of test units per dilution)
13
Viral identification
•
•
•
•
•
•
•
•
Complement fixation：
Hemagglutination inhibition
Neutralization
Immunofluorescence ( direct or indirect)
Latex agglutination
In situ EIA
ELISA
RIA(radioimmuno
14
Laboratory Diagnosis
•
•
•
•
•
Microscopy Identification
Virus isolation and identification
Detection of viral proteins( antigens and enzymes)
Detection of viral genetic material
Serologic procedures
15
Detection of viral proteins
( antigens and enzymes)
•
•
•
•
Antigen detection ( ELISA, RIA, Western blot)
Hemagglutination and hemadsorption
Enzyme activities( reverse transcriptase)
Protein patterns( electrophoresis )
16
Laboratory Diagnosis
•
•
•
•
•
Microscopy Identification
Virus isolation and identification
Detection of viral proteins( antigens and enzymes)]
Detection of viral genetic material
Serologic procedures
17
Detection of viral genetic material
• PCR ( Polymerase chain reaction)
• RT-PCR (Reverse transcriptase polymerase chain
reaction)
• Southern（DNA), Northern(RNA), and dot blots
• DNA genome hybridization in situ(cytochemistry)
• Electrophoretic mobilities of RNA for segmented RNA
viruses( Electrophoresis)
• Restriction endonuclease cleavage patterns
18
Laboratory Diagnosis
•
•
•
•
•
Microscopy Identification
Virus isolation and identification
Detection of viral proteins( antigens and enzymes)]
Detection of viral genetic material
Serologic procedures
19
Serologic procedures
• If the antibody titer in the convalesent-phase
serum sample is at least 4-fold higher than the
titer in the acute-phase serum sample, the patient
is considered to be infected.
• In certain viral diseases, the presence of IgM
antibody is used to diagnose current infection
• Other nonspecific serologic tests are available
20
Serologic procedures
•
•
•
•
•
•
•
•
Complement fixation：
Hemagglutination inhibition
Neutralization
Immunofluorescence ( direct or indirect)
Latex agglutination
In situ EIA
ELISA
RIA
21
Viruses Diagnosed by Serology
•
•
•
•
•
•
Epstein-Barr virus
Rubella virus
Hepatitis A, B, C, D, and E viruses
HIV
Human T-cell Leukemia virus
Arboviruses ( Encephalitis viruses)
22
Prevention
•
Successes of the Past
• Possibilities for the Future
23
Active immunization
Vaccines
24
Overview of Active immunization
•
Active immunization - administration of
antigen resulting in production of a specific
immune response with immunologic
memory. Response may be cellular or
humoral or both.
 Natural immunity - to diseases you have
caught and successfully fought
 Artificial immunity – Vaccination(vaccines)
25
Attributes of a good vaccine
• Ability to elicit the appropriate immune response for
the particular pathogen
• Long term protection ideally life-long
• Safety vaccine itself should not cause disease
• Stable retain immunogenicity, despite adverse
storage conditions prior to administration
• In-expensive
26
LIVE VACCINES
• Live attenuated organism
• Heterologous vaccines
• Live recombinant vaccines
•
Attributes – live vaccines
27
Live attenuated organism
• Organisms whose virulence has been
artificially reduced by in vitro Culture under
adverse conditions, such as reduced
temperature.
28
Heterologous vaccines
• Closely related organism of lesser virulence,
which shares many antigens with the virulent
organism. The vaccine strain replication in
the host and induces an immune response
that cross reacts with antigens of the virulent
organism.
• Vaccinia virus /cowpox virus--- Variola virus
29
Live recombinant
• Vector
1. bovine vaccine
2. BCG
30
Advantages of Attenuated
Vaccines 2-1
•Both cell mediated immunity and antibody response
•Activates all phases of immune system. Can get
humoral IgG and local IgA
•Raises immune response to all protective antigens.
Inactivation may alter antigenicity.
•More durable immunity; more cross-reactive
•Immunity is long lived
•Single dose
31
Advantages of Attenuated
Vaccines 2-2
• Low cost
• Quick immunity in majority of vaccinees
• In case of polio and adeno vaccines, easy
administration
• Easy transport in field
• Can lead to elimination of wild type virus from
the community
32
Disadvantages of Live Attenuated Vaccine
• Mutation; reversion to virulence (often frequent)
•Spread to contacts of vaccinee who have not
consented to be vaccinated (could also be an
advantage in communities where vaccination is not
100%)
• Spread vaccine not standardized--may be backmutated
• Poor "take" in tropics
• Problem in immunodeficiency disease (may spread to
these patients)
33
Killed vaccines
• The organism is propagated in bulk, in vitro,
and inactivated with either beta-propiolactone
or formaldehyde. These vaccines are not
infectious and are therefore relatively safe.
However, they are usually of lower
immunogenicity and multiple doses may be
needed to induce immunity. In addition, they
are usually expensive to prepare.
34
Killed vaccines
• Inactivated organism: rabies virus;
epidmic type B encephalitis virus.
• Subunit Vaccines: Influenza virus( HA and
NA)
• Recombinant proteins: HBV
35
Advantages of inactivated
vaccines
• Gives sufficient humoral immunity if
boosters given
• No mutation or reversion
• Can be used with immuno-deficient
patients
• These vaccines tend to be able to
withstand more adverse storage
conditions,Sometimes better in tropics
36
Disadvantages of inactivated
vaccines
• Many vaccinees do not raise immunity
• poor, only antibody, no cell immediated
immune response
• response is short-lived and multiple doses
are needed
• No local immunity (important)
• Inactivated, therefore can not replicate in
the host and cause disease
• Failure in inactivation and immunization
with virulent virus
• Expense: Expensive to prepare
37
New Methods
Selection of attenuated virus strain
• Varicella
• Hepatitis A
Use monoclonal antibodies to select for virus with altered surface
receptor
• Rabies
• Reo
Use mutagen and grow virus at 32 degrees. Selects for
temperature-sensitive virus. Grows in upper respiratory tract but not
lower
• ‘flu (new vaccine)
• respiratory syncytial virus
38
New Methods
Passage progressively at cold temperatures
TS mutant in internal proteins
Can be re-assorted to so that coat is the strain that is
this years flu strain
39
PB2
PB1
PA
HA
NA
NP
M
NS
Attenuated Donor
Master Strain
Attenuated Vaccine Strain:
Coat of Virulent strain with
Virulence Characteristics of
Attenuated Strain
X
PB2
PB1
PA
HA
NA
NP
M
NS
PB2
PB1
PA
HA
NA
NP
M
NS
New Virulent
Antigenic Variant
Strain
40
New Methods
Deletion mutants
• Suppression unlikely (but caution in HIV)
• Viable but growth restrictions
Problems
• Oncogenicity in some cases (adeno, retro)
41
New Methods
• Recombinant DNA
•Single gene (subunit)
Hepatitis B
vaccine
S-antigen mRNA
cDNA
raised in yeast
Express plasmid
S-antigen mRNA
protein
42
Single gene (subunit) - problems
• Surface
glycoprotein poorly soluble deletion?
• Poorly immunogenic
• Post-translational modifications
• Poor CTL response
43
Single gene (subunit) in
expression vector
Vaccinate with live virus
Canary Pox
• Infects human cells but does not replicate
• Better presentation
• CTL response
Vaccinia
Attenuated Polio
Being developed for anti-HIV vaccine
44
New Methods
Chemically synthesized peptide
• malaria
poorly immunogenic
45
New methods
Anti-idiotype vaccine
Virus
epitope
antibody
Antibody
with epitope
binding site
46
Anti-idiotype vaccine cont
Antiidiotype
antibody
antibody
Make antibody
against antibody
idiotype
Anti-idiotype
antibody mimics the
epitope
47
Anti-idiotype antibody cont 2
Use anti-idiotype antibody as
injectable vaccine
Anti-idiotype
antibody
Use as vaccine
Binds and
neutralizes virus
Anti-anti-idiotype
antibody
Anti-anti-idiotype
antibody
Antibody to anti-idiotype
antibody
Anti-anti-idiotype
antibody
48
New Methods
New “Jennerian Vaccines”
• Live vaccines derived from animal strains of
similar viruses
• Naturally attenuated for humans
Rotavirus: Monkey Rota
80% effective in some human populations
Ineffective in others
49
Due to differences in circulating viral serotypes
New Methods
New Jennerian Vaccines
Bovine parainfluenza Type 3
Bovine virus is:
• Infectious to humans
• Immunogenic (61% of children get good
response)
• Poorly transmissable
•Phenotypicaly stable
50
New Methods
Second Generation Jennerian Vaccines
Rotavirus
11 segments of double strand RNA
Two encode:
• VP4 (hemagglutinin)
• VP7 (glycoprotein)
Co-infect tissue culture cells
Elicit neutralizing
antibodies
reassortment
•10 segments from monkey rotavirus
• 1 segment outer capsid protein of each of four major rotavirus strains
Efficacy >80%
51
Vaccines
• 1796 Jenner: wild type animal-adapted
virus
• 1800’s Pasteur: Attenuated virus
• 1996 DNA vaccines
The third vaccine revolution
52
DNA vaccines
• DNA vaccines are at present experimental ,
but hold promise for future therapy since they
evoke both humoral and cell-mediated
immunity, without the dangers associated
with live virus vaccines
53
DNA Vaccines
Gene for
antigen
plasmid
Muscle cell
Muscle cell expresses
protein - antibody made
54
CTL response
DNA Vaccines
• Plasmids are easily manufactured in large amounts
• DNA is very stable
• DNA resists temperature extremes so storage and
transport are straight forward
• DNA sequence can be changed easily in the laboratory.
This means that we can respond to changes in the
infectious agent
• By using the plasmid in the vaccinee to code for antigen
synthesis, the antigenic protein(s) that are produced are
processed (post-translationally modified) in the same way
as the proteins of the virus against which protection is to
be produced. This makes a far better antigen than
purifying that protein and using it as an immunogen.
55
DNA Vaccines
• Mixtures of plasmids could be used that encode many
protein fragments from a virus/viruses so that a broad
spectrum vaccine could be produced
• The plasmid does not replicate and encodes only the
proteins of interest
• No protein component so there will be no immune response
against the vector itself
• Because of the way the antigen is presented, there is a CTL
response that may be directed against any antigen in the
pathogen. A CTL response also offers protection against
diseases caused by certain obligate intracellular pathogens56
(e.g. Mycobacterium tuberculosis)
DNA Vaccines
Possible Problems
• Potential integration of plasmid into host
genome leading to insertional mutagenesis
• Induction of autoimmune responses (e.g.
pathogenic anti-DNA antibodies)
• Induction of immunologic tolerance (e.g. where
the expression of the antigen in the host may lead
to specific non-responsiveness to that antigen) 57
DNA Vaccines
DNA vaccines produce a situation that reproduces a virallyinfected cell
Gives:
• Broad based immune response
• Long lasting CTL response
Advantage of new DNA vaccine for flu:
CTL response can be against internal protein
In mice a nucleoprotein DNA vaccine is effective against a range of viruses
58
with different hemagglutinins
Adjuvants
• Certain substances, when administered
simultaneously with a specific antigen, will
enhance the immune response to that
antigen.
59
Adjuvants in common use
• Aluminium salts
• Liposomes and immunostimulating complexes
• Complet Freund’s adjuvant is an emulsion of
mycobacteria, oil and water
• Incomplete Freund’s adjuvant
• Muramyl di-peptide
• Cytokines
60
Possible action modes of adjuvant
• By trapping antigen in the tissues, thus
allowing maximal exposure to dendritic cells
and specific T and B lymphocytes
• By activating antigen-presenting cells to
secrete cytokines that enhance the
recruitment of antigen-specific T and B cells
to the site of inoculation
61
Smallpox
62
Smallpox
• Variolation
•1% v. 25%
mortality
•Life-long immunity
• No drift or shift
63
Smallpox
Vaccination
• Jenner 1796 : Cowpox/Swinepox
• 1800’s Compulsory childhood
vaccination
• 1930’s Last natural UK case
• 1940’s last natural US case
• 1958 WHO program
• October 1977: Last case
(Somalia)
64
Smallpox • No animal reservoir
• Lifelong immunity
• Subclinical cases rare
• Infectivity does
not precede overt symptoms
• One Variola serotype
• Effective vaccine
65
• Major commitment by governments
polio
• Killed virus vaccine(Salk, 1954)
• Live attenuated oral polio vaccine( Sabin,
1957)
• The inactivated Salk vaccines is
recommended for children who are
immunosuppressed.
•
66
Polio Vaccine
Small RNA virus
Some drift…but not too far as non-viable
Sabin attenuated vaccine
~ 10 cases vaccine-associated disease per year
• 50% vaccinees
feces
• 50% contacts
• Vaccine-associated cases: revertants
• 1 in 4,000,000 vaccine infections
paralytic polio
• 1 in 100 of wt infections
Scandinavia: Salk dead vaccine
• No gut immunity
67
• Cannot wipe out wt virus
Reported cases per 100000 population
100
Inactivated
(Salk) vaccine
Cases per 100,000
population United
States
10
Oral
vaccine
1
0.1
0.01
0.001
1950
1960
1970
1980
1990
68
Total cases
Sweden and Finland
10000
Reported cases
Killed (Salk)
vaccine
1000
100
10
1
0
1950
1955
1960
1965
1970
1975
69
Reciprocal virus antibody titer
512
Killed
(Salk)
Vaccine
Live
(Sabin)
Vaccine
Serum IgG
Serum IgG
128
32
Serum IgM
Serum IgM
Nasal IgA
Serum IgA
8
Serum IgA
2
Duodenal IgA
Nasal and
duodenal IgA
1
48
Vaccination
96
48
96
70
Days
Vaccination
Sabin Polio Vaccine
Attenuation by passage in foreign host
More suited to foreign environment and less suited to original
host
Grows less well in original host
Polio:
• Monkey kidney cells
• Grows in epithelial cells
• Does not grow in nerves
• No paralysis
•Local gut immunity (IgA)
Pasteur rabies vaccine also attenuated
71
Salk Polio Vaccine
•
Formaldehyde-fixed
• No reversion
72
Polio Vaccine
Why use the Sabin vaccine?:
• Local immunity: Vaccine virus just like natural infection
• Stopping replication in G.I. Tract stops viral replication
TOTALLY
• Dead Salk vaccine virus has no effect on gut replication
• No problem with selective inactivation
• Greater cross reaction as vaccine virus also has antigenic drift
• Life-long immunity
73
Measles
• Live attenuated virus grown in chick embryo
fibroblasts, first introduced in the 1960’s.
• Etiology: Measles virus
• Incubation: 8 to 12 days
• Clinical Manifestations: cough, coryza, conjunctivitis
, erythematous maculopapular rash
fever ,Koplik Spots ,complictions include Encephalitis,
Pneumonia, and SSPE
• Treatment: Supportive
74
Mumps
•
•
•
•
•
•
•
Live attenuated virus developed in the 1960’s
MMR vaccine
Etiology: Mumps Virus
Incubation: 16 to 18 days
Clinical Manifestations:
swelling of the salivary glands
complications include Meningitis, Orchitis,
Encephalitis, and Deafness
75
rubella
•
•
•
•
•
Live attenuated virus
Etiology: Rubella Virus
Incubation: 14 to 21 days
Clinical Manifestations: Congenital , cataracts
patent ductus arteriosus , deafness mental
retardation , Postnatal mild disease , erythematous
maculopapular rash , postauricular
lymphadenopathy transient polyarthralgias
76
Hepatitis B
• Two vaccines are in current use:
A serum derived vaccine
A recombinant vaccine
• Etiology: Hepatitis B Virus
• Incubation: 120 days (average)
• Clinical Manifestations: jaundice ; anorexia
• nausea and vomiting ; malaise
• complications include the development of a chronic
carrier state with a high risk for Hepatocellular
Carcinoma (liver cancer)
77
Hepatitis A
• Formalin-inactivated , cell cultured-derived
virus,
78
Yellow fever
• The 17D strain is a live attenuated vaccine
developed in 1937.
• It is a highly effective vaccine which is
administered to residents in the tropics and
travellers to endemic areas.
79
Rabies
No safe attenuated strain of rabies virus has yet
been developed for human. Vaccines in current
use include: a] The neurotissue vaccine
b] human diploid cell culturederived vaccine, which is much safer.
There are two situation where vaccine is given: a]
Post-exposure prophylaxis, followinf the bite of a
rabid animal, Hyperimmune rabies globulin may
also administered .
b] Pro-exposure prophylaxis is used for
protection of those occupation puts them at risk
80
of infection with rabies.
Influenza
• New vaccines are produced every year
81
Varicella-Zoster virus
• Not licensed vaccines
82
83
Passive Immunisation
84
Modes of immunization
• Passive immunization - administration of antibodycontaining serum to provide immediate, but temporary
protection. Doesn't activate a lasting specific immune
response.
85
Natural
• Provides immunity for diphtheria, tetanus,
streptococcus, rubeola (red measles), rubella
(German measles), mumps, polio, and
others.
86
Artificial
• Often used as antitoxins for things such as
black widow spider and snake bites, botulism,
and tetanus. Important for some infectious
diseases such as rabies, since it provides
immediate protection rather than waiting the
7-10 days for a protective response to
develop from active immunization.
87
Immunoglobulin
• “Normal”Immune globulin
• Hyper-immune globulin
88
“Normal”Immune globulin
Low titres of antibody to a wide range
of human viruses
• Hepatitis A virus infection
• Parvovirus infection
• Enterovirus infections (in neonates)
• HIV-infected babies
89
Hyper-immune globulin
--- high titres of antibody to particular viruses
• Zoster immune globulin: prevention of varicella in
immunocompromised children and neonates
• Human rabies immunoglobulin: post-exposure
prophylaxis in an individual who has been bitten by
a rabid animal
• Hepatitis B immune globulin:non-immune individal
who has been exposed to HBV
• RSV immune globulin: treatment of respiratory
syncitial virus infections in the very young
90
Antiviral Therapy
91
Antiviral Therapy
•
•
•
•
Antiviral chemotherapy
Interferon
Gene therapy
Chinese Herbs
92
Antiviral chemotherapeutic Agents
• Antiviral drugs are available to treat only a
few viral diseases.
• The reason for this is the fact that viral
replication is so intimately associated with the
host cell that any drug that interferes
significantly with viral replication, is likely to
be toxic to the host
93
Targets for chemotherapeutic
agents
•
•
•
•
•
Attachment to host cell
Uncoating –(amantadine)
Synthesis of viral mRNA-(interferon)
Translation of mRNA-(interferon)
Replication of viral RNA or DNA- (nucleoside
anologues)
• Maturation of new virus proteins-(protease
inhibitors)
• Budding , release
94
95
Diseases for which effective
therapy is available
• AIDS:
Zidovudine叠氮胸苷+ Lamivudine拉米夫定+ protease
inhibitors
•
•
•
•
Influenza: Amantadine
Herpes simplex virus: Acyclovir
Varicella-Zoster virus: Acyclovir
Cytomegalovirus : Gancyclovir更昔洛韦, Foscarnet
膦甲酸
• Respiratory syncitial virus: Ribavirin利巴韦林
96
Nucleotide analogues
• Nucleotide analogues competes with
normal nucleotide for incorporation into
viral DNA or RNA.
97
Interferon
• Direct antiviral effect ( prevents the infection
of new cells) by a) degradation of viral
mRNA, and b) inhibition of protein synthesis
• Enhancement of the specofic
immuneresponse by increasing the
expression of MHC class I molecules on the
surface of infected cells, the interferons
increase the opportunity for specifif cytotoxic
T cells to recognise and kill infected cells
• Chronic hepatitis B and C virus
98
Chinese Herbs
• 板蓝根、大青叶、苍术、艾叶。
• 双黄连
99